In ovarian cancer and fibromasarco, Tspan29 inhibits cell proliferation and migration by affecting several β1 integrin subpopulations or forming EWI-2/EWI-F/β1 complexes, inactivating AKT, p38, and EGFR signaling pathways [34, 35]. This evidence concerns the gene CD9 and ovarian carcinoma.